Jeff Yass’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,427,100
| Closed | -$103M | – | 13968 |
|
|
2025
Q4 | $103M | Buy |
1,427,100
+1,231,100
| +628% | +$79.5M | 0.01% | 867 |
|
|
2025
Q3 | $8.54M | Buy |
196,000
+127,500
| +186% | +$5.15M | ﹤0.01% | 3250 |
|
|
2025
Q2 | $1.95M | Sell |
68,500
-42,500
| -38% | -$1.27M | ﹤0.01% | 5842 |
|
|
2025
Q1 | $3.28M | Buy |
111,000
+98,900
| +817% | +$3.08M | ﹤0.01% | 4483 |
|
|
2024
Q4 | $352K | Sell |
12,100
-24,200
| -67% | -$1.01M | ﹤0.01% | 9472 |
|
|
2024
Q3 | $1.67M | Sell |
36,300
-100,100
| -73% | -$4.34M | ﹤0.01% | 5669 |
|
|
2024
Q2 | $5.57M | Buy |
136,400
+85,500
| +168% | +$2.45M | ﹤0.01% | 3276 |
|
|
2024
Q1 | $1.3M | Buy |
50,900
+23,600
| +86% | +$370K | ﹤0.01% | 6302 |
|
|
2023
Q4 | $247K | Buy |
+27,300
| New | +$182K | ﹤0.01% | 10239 |
|
|
2023
Q3 | – | Sell |
-21,700
| Closed | -$241K | – | 12822 |
|
|
2023
Q2 | $241K | Buy |
+21,700
| New | +$272K | ﹤0.01% | 9892 |
|
|
2023
Q1 | – | Sell |
-67,800
| Closed | -$1.5M | – | 13348 |
|
|
2022
Q4 | $1.5M | Buy |
+67,800
| New | +$1.01M | ﹤0.01% | 5277 |
|
Other funds holding RNAM
Jeff Yass's RNAM Position: Q1 2026 in Review
Jeff Yass sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 268,393 shares — an estimated $19.4M sold.
Jeff Yass first reported a position in RNAM in Q3 2020 and held it in 21 quarters. The position peaked at $19.4M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Jeff Yass reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Jeff Yass sold 268,393 Avidity Biosciences shares in Q1 2026, an estimated $19.4M.
- Jeff Yass first reported a position in Avidity Biosciences in Q3 2020 and held it in 21 quarters.
- Jeff Yass's Avidity Biosciences position peaked at $19.4M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.